27 July 2012
Cell Medica raises $26.5m
Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.
Author: Toby Lewis, editor, Global Corporate Venturing
Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, have helped UK-basedcell therapy developer Cell Medica raise £17m ($26.5m).
The Cancer Prevention and Research Institute of Texas has also offered $15.3m to back Cell Medica's cancer immunotherapy technology licensed from Baylor College of Medicine.
Thomas Hecht, the former vice president of marketing in Europe for Amgen is becoming chairman and UK-based foundation the Wellcome Trust is converting its investment in the company into equity.
Supporting articles: Those who can, must do so / Imperial rules Abingdon Health / Imperial Innovations has $177m war chest / PolyTherics gains Pitchford as director / Intel, UCL, Imperial link on Sustainable Cities / Imperial Innovations, Oxford inject funds into Oxford Immunotec / Spin-outs decline in UK / Abingdon Health buys Forsite / Imperial helps PsiOxus raise $34m
Copyright Mawsonia Limited 2010. Please don´t cut articles from www.globaluniversityventuring.com or the PDF and redistribute by email or post to the web without written permission.